Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-BTK Antibody (R3R23)

Catalog #:   RHG07802 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1
Applications: IF, IHC, WB
Accession: Q06187
Overview

Catalog No.

RHG07802

Species reactivity

Human, Monkey

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

IF: 1:200-1:1000, IHC: 1:200-1:1000, WB: 1:500-1:2000

Target

BPK, Tyrosine-protein kinase BTK, AGMX1, Agammaglobulinemia tyrosine kinase, Bruton tyrosine kinase, BTK, ATK, B-cell progenitor kinase

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q06187

Applications

IF, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3R23

Data Image
  • Immunofluorescence
    Immunofluorescence analysis of Jurkat cells using BTK mouse mAb.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human lymph-node tissues (left) and human lymph follicle tissues (right), showing cytoplasmic and membrane localization using BTK mouse mAb with DAB staining.
  • Western blot
    Western blot analysis using BTK mouse mAb against K562 (1), MCF-7 (2), Jurkat (3) and HEK293 (4) cell lysate.
References

Immunohistochemical Study of the Localization of Ibrutinib-Protein Conjugates in the Rat Gastrointestinal Tract., PMID:40535471

Marginal Zone Lymphoma: Treatment Update With a Focus on Systemic Approaches., PMID:40517548

Advances in the Management of Relapsed/Refractory CLL and Richter Transformation., PMID:40517442

Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia., PMID:40515863

Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies., PMID:40475129

Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia., PMID:40472329

Antibody-Directed Cell Internalization of Targeted Covalent Europium Tag Enables In Situ Kinase Labeling and Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Quantification., PMID:40470552

Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia., PMID:40456120

Evaluating remibrutinib in the treatment of chronic spontaneous urticaria., PMID:40455080

Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors., PMID:40379542

The new era of primary immune thrombocytopenia management in adults: A narrative review of current and emerging treatments., PMID:40374446

Treatment of Anti-Myelin-Associated Glycoprotein (MAG) Antibody Neuropathy Using Zanubrutinib in a Patient With Waldenström Macroglobulinemia: A Clinical Vignette., PMID:40351903

New Frontiers in Multiple Sclerosis Treatment: From Targeting Costimulatory Molecules to Bispecific Antibodies., PMID:40332536

The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis., PMID:40327539

Efficacy and Safety of Rilzabrutinib in Patients With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Proof-of-Concept Phase II Clinical Trial., PMID:40317187

Chronic lymphocytic leukemia: what clinical progress have we seen in the last five years?, PMID:40314223

Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma., PMID:40278919

Long term follow-up of MRD guided treatment of Ibrutinib plus Venetoclax for Relapsed CLL: phase 2 VISION/HO141 trial., PMID:40249856

Critical roles of chronic BCR signaling in the differentiation of anergic B cells into age-associated B cells in aging and autoimmunity., PMID:40249819

AMPLIFY: A second-generation BTK inhibitor for fixed-duration therapy in chronic lymphocytic leukemia., PMID:40220751

Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukaemia., PMID:40209064

[Update on marginal zone lymphoma classification, diagnosis and treatment in 2024]., PMID:40157832

Comparing novel treatments in chronic spontaneous urticaria: A critical appraisal of Bruton's tyrosine kinase inhibitors versus anti-cytokine biologics in clinical trials., PMID:40148228

Mantle cell lymphoma: from pathogenesis to treatment for 2024 and beyond., PMID:40146175

Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy., PMID:40084099

Update on the Treatment of Chronic Spontaneous Urticaria., PMID:40074986

Effects of orelabrutinib, a BTK inhibitor, on antibody-mediated platelet destruction in primary immune thrombocytopenia., PMID:40069128

BTK inhibitors enhance NKG2D ligand expression by regulating IL-10/STAT3 pathway in activated non-GCB diffuse large B-cell lymphoma cells., PMID:40029697

SOHO State of the Art Updates and Next Questions | Novel Immunotherapy Combinations for the Treatment of Indolent B-Cell Lymphoma., PMID:40011100

Strongyloides stercoralis infection in a DLBCL patient treated with rituximab and BTK inhibitor: A case report and literature review., PMID:39993065

Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma., PMID:39967670

BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL., PMID:39941922

Improving Treatment Options for Patients with Double Refractory CLL., PMID:39941798

Case report: Therapeutic use of bortezomib in a patient with Schnitzler syndrome., PMID:39935483

Molecular Mechanisms and Therapeutic Prospects of Immunotherapy and Targeted Therapy in Primary Central Nervous System Lymphoma., PMID:39912261

Pseudomonas aeruginosa sepsis with sacroiliitis in X-linked agammaglobulinaemia., PMID:39900389

Challenges in the Management of a Difficult-to-Treat Patient With Hairy Cell Leukemia: A Case Report., PMID:39886728

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial., PMID:39883943

Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction., PMID:39846984

From phenotypic to molecular diagnosis: Insights from a clinical immunology service focused on inborn errors of immunity in Colombia., PMID:39836844

The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics., PMID:39827471

Increased Phosphorylation of Intracellular Signaling Molecules Indicates Continuous Activation of Human Autoreactive B-Cells., PMID:39821328

Inhibition of Bruton's tyrosine kinase restricts neuroinflammation following intracerebral hemorrhage., PMID:39744694

Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia., PMID:39716442

One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID-19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic., PMID:39711119

[Updates on hairy cell leukemia (HCL) and HCL-like disorders]., PMID:39710534

Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study., PMID:39685948

The evolving frontline management of CLL: are triplets better than doublets? How will we find out?, PMID:39644005

[Single-center study of COVID-19 in patients with chronic lymphocytic leukemia]., PMID:39622756

Therapies for Chronic Spontaneous Urticaria: Present and Future Developments., PMID:39598410

Datasheet

Document Download

Anti-BTK Antibody (R3R23).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-BTK Antibody (R3R23) [RHG07802]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only